Regeneron Pharmaceuticals (REGN) is back in focus after law firm Bronstein, Gewirtz & Grossman announced a securities class action tied to disclosures around the Phase III Fianlimab Libtayo trial.

Although Regeneron (currently trading at $845.04 per share) has gained 8.1% over the last six months, it has trailed the S&P ...

Harbor Funds, an investment management company, released its Q2 2026 investor letter for “Harbor Mid Cap Value Fund”. The ...

Shares of biotech company Regeneron (NASDAQ:REGN) fell 10.5% in the afternoon session after its experimental cancer treatment failed to meet the main goal in a late-stage study for patients with a ...

On May 15, 2026, Regeneron issued a press release announcing that the "Phase 3 Trial of Fianlimab . . . did not reach ...

Here’s why we believe Regeneron Pharmaceuticals (REGN) stock merits attention as a value addition. Currently, it is trading almost 44% lower than its 1-year peak and is also priced at a PS multiple ...

Here is why we believe Regeneron Pharmaceuticals (REGN) stock is worthy of consideration as a value investment. It is presently trading nearly 38% lower than its one-year peak, and is also being ...

Investors in Regeneron Pharmaceuticals, Inc. (Symbol: REGN) saw new options become available today, for the September 2026 expiration. One of the key data points that goes into the price an option ...

Morgan Stanley 24th Annual Global Healthcare Conference September 14, 2026 1:05 PM EDTCompany ParticipantsRyan ...